Health condition · Clinically reviewed
Bladder cancer, haematuria pathway, intravesical BCG and modern immunotherapy.
Non-muscle-invasive vs muscle-invasive bladder cancer are treated very differently. The haematuria 2-week-wait pathway catches most; modern intravesical BCG and immunotherapy have transformed outcomes.
Why trust this guide
- 01
Clinically reviewed
Written by our editorial team and reviewed by a registered UK clinician before publication.
- 02
Sourced, not summarised
Every claim is checked against NICE, EAU or a peer-reviewed source you can see at the end.
- 03
Updated for 2026
Reflects current UK guidance on the haematuria 2-week-wait pathway, intravesical BCG and modern immunotherapy.
Key facts
Bladder cancer at a glance.
The essentials, in plain English — what it is, how it shows up, how it’s diagnosed in the UK today, and how treatment is chosen.
-
What it is
Urothelial carcinoma is the most common type — cancer arising from the lining of the bladder.
-
Biggest risk factor
Smoking is the single biggest risk factor for bladder cancer — stopping reduces recurrence too.
-
Two very different diseases
Non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) bladder cancer are treated very differently.
-
How it shows up
Painless visible haematuria is present in more than 90% of new cases — always investigate.
-
NMIBC treatment
TURBT plus intravesical BCG for high-risk non-muscle-invasive disease.
-
MIBC treatment
Radical cystectomy or bladder-preserving chemoradiotherapy for muscle-invasive disease.
Why this guide matters
Two very different diseases under one name.
Non-muscle-invasive and muscle-invasive bladder cancer follow very different pathways. Both start with the same clue — blood in the urine.
-
Never ignore visible haematuria
Painless blood in the urine is the classic sign — it justifies an urgent 2-week-wait urology referral every time.
-
Cystoscopy is the definitive test
Flexible cystoscopy under local anaesthetic is quick, safe and the gold standard for looking inside the bladder.
-
Risk group drives treatment
NMIBC and MIBC follow very different paths — from BCG surveillance to cystectomy or bladder-preserving chemoradiotherapy.
How the diagnosis is made
From first haematuria to a clear plan.
The 2-week-wait haematuria pathway UK uro-oncology teams follow, in order — so you know what to expect and why.
Phase 1 · Assessing
Haematuria triage, cystoscopy and cytology
Phase 2 · Confirming
Upper-tract imaging and TURBT
Phase 3 · Planning
MRI staging and MDT decision
- 01
Assessing
Visible or persistent microscopic haematuria
Any visible blood in the urine, or persistent non-visible haematuria, is the trigger for urgent investigation.
- 02
Assessing
Urgent flexible cystoscopy (2WW)
A thin telescope inspects the bladder lining under local anaesthetic — the definitive first-line test.
- 03
Assessing
Urinary cytology
A urine sample is checked for cancer cells, especially useful for high-grade and carcinoma in situ disease.
- 04
Confirming
Upper-tract imaging (CT urogram)
A CT urogram examines the kidneys and ureters — the whole urothelium can be affected, not just the bladder.
- 05
Confirming
TURBT + histology + risk stratification
Transurethral resection of the bladder tumour provides tissue for grade, stage and risk grouping.
- 06
Planning
MRI pelvis for MIBC
Muscle-invasive disease is staged with MRI to plan surgery or bladder-preserving chemoradiotherapy.
- 07
Planning
Uro-oncology MDT
A specialist multi-disciplinary team recommends the treatment options that fit your risk group and preferences.
Typical timeline: 4–8 weeks from haematuria referral to a treatment plan.
Symptoms
What bladder cancer actually shows up as.
More than 90% of new bladder cancers show painless visible haematuria. When symptoms appear, they matter — here is what to watch for and when to act.
-
Painless haematuria
Visible blood in the urine, without pain, is the classic presentation — always investigate on a 2-week-wait pathway.
-
LUTS with haematuria
Frequency, urgency or dysuria alongside blood in the urine deserves urgent urology assessment.
-
Suprapubic pain
New persistent pain low in the abdomen, especially with urinary change, needs investigation.
-
Palpable mass
A pelvic or suprapubic mass on examination is a late sign that needs urgent imaging.
-
Loin pain (upper-tract obstruction)
Loin or flank pain can signal a tumour blocking the ureter and causing hydronephrosis.
-
Constitutional symptoms
Unexplained weight loss, fatigue or night sweats in someone with haematuria raises concern for advanced disease.
-
Recurrent UTIs
Recurrent or antibiotic-resistant urinary infections, especially with haematuria, warrant cystoscopy.
-
Red flag
Massive haematuria with clot retention — same-day urology assessment or A&E.
Treatment
How bladder cancer is treated in the UK.
Treatment is chosen by risk group and stage — from TURBT plus intravesical therapy for NMIBC, to cystectomy, chemoradiotherapy and modern immunotherapy for advanced disease.
-
TURBT
Transurethral resection of the bladder tumour — both diagnostic and the first treatment for non-muscle-invasive disease.
-
Intravesical BCG
A course of BCG instilled into the bladder stimulates a local immune response — the standard for high-risk NMIBC.
-
Intravesical mitomycin
A single post-TURBT dose reduces recurrence; a course is used for intermediate-risk NMIBC.
-
Radical cystectomy + ileal conduit / neobladder
Removal of the bladder with urinary diversion — the standard surgical option for muscle-invasive disease.
-
Bladder-preserving chemoradiotherapy
Combined chemotherapy and radiotherapy — a bladder-sparing alternative to cystectomy for selected patients.
-
Neoadjuvant cisplatin-based chemo
Cisplatin-based chemotherapy before cystectomy improves survival in fit patients with muscle-invasive disease.
-
Immunotherapy (pembrolizumab, nivolumab, avelumab)
Checkpoint inhibitors have transformed outcomes in BCG-unresponsive and advanced bladder cancer.
-
Enfortumab vedotin (advanced)
An antibody-drug conjugate for advanced urothelial cancer after platinum chemotherapy and immunotherapy.
What this guide is based on
The sources behind every number on this page.
UK and European guidance, specialist society standards and patient-organisation resources, current at the time of last review.
Key references
Guidelines and standards we relied on.
A quiet reminder
This guide is for information, not medical advice.
Your GP or uro-oncology team knows your history and can tell you which parts apply to you.
-
National Institute for Health and Care Excellence (NICE). Bladder cancer: diagnosis and management (NG2).
-
European Association of Urology (EAU). Guidelines on non-muscle-invasive and muscle-invasive bladder cancer.
-
Fight Bladder Cancer UK. Patient information and support resources.
-
British Uro-oncology Group / UK Uro-oncology consensus statements.
Red flags
When bladder cancer becomes an emergency.
Most of the time, bladder cancer follows a planned pathway. These are the situations where it needs same-day help.
-
Massive haematuria + clot retention
Heavy visible bleeding with inability to pass urine due to clots — same-day urology, may need bladder washout.
-
Upper-tract obstruction / hydronephrosis
Loin pain with rising creatinine or hydronephrosis on scan needs urgent decompression.
-
Post-TURBT bleed / perforation
Heavy bleeding or severe pain after a bladder resection needs same-day urology assessment.
-
BCG sepsis
Fever, rigors and systemic upset after intravesical BCG — a rare but serious complication needing urgent admission.
-
Post-cystectomy leak
Fever, abdominal pain or reduced output from a stoma after cystectomy needs urgent surgical review.
-
Neutropenic sepsis
Fever within 6 weeks of chemotherapy — attend A&E immediately, do not wait for a GP appointment.
-
Metastatic bone pain
New persistent bone pain in known bladder cancer warrants urgent imaging.
-
Malignant obstruction of the ureter
Progressive renal impairment from tumour obstruction may need stenting or nephrostomy.
-
Palliative-stage crisis
Uncontrolled bleeding, pain or delirium in advanced disease — contact your specialist palliative team urgently.
Living with it
A long-term journey, with structured surveillance.
Four things that make the biggest difference day to day — surveillance, stopping smoking, life after cystectomy and specialist follow-up.
A quiet reminder
Ask about smoking support early.
Stopping smoking reduces recurrence and progression — ask your team to refer you to a structured stop-smoking service.
- 01 Monitoring
Surveillance cystoscopy
Regular flexible cystoscopy is the backbone of follow-up after TURBT — schedule depends on your risk group.
- 02 Lifestyle
Stopping smoking really helps
Stopping smoking reduces the risk of recurrence and progression — ask for structured support early.
- 03 Stoma & body
Life after cystectomy
Stoma care, sexual function and continence all need specialist support — clinical nurse specialists make a big difference.
- 04 Reviews
Structured uro-oncology follow-up
Regular reviews with cystoscopy, imaging and cytology keep surveillance on track and catch recurrence early.
Frequently asked
Everything we get asked about bladder cancer.
Quick answers on haematuria, cystoscopy, BCG, cystectomy and when to worry.
-
What is bladder cancer?
Bladder cancer is a cancer of the lining of the bladder. Urothelial (transitional cell) carcinoma is by far the most common type in the UK.
-
What is the difference between NMIBC and MIBC?
Non-muscle-invasive bladder cancer (NMIBC) is confined to the inner lining and is usually treated with TURBT and intravesical therapy. Muscle-invasive bladder cancer (MIBC) has grown into the muscle wall and is treated with cystectomy or chemoradiotherapy.
-
Should I always investigate blood in my urine?
Yes. Visible haematuria — especially painless — is the most common presentation of bladder cancer, so a 2-week-wait urology referral for cystoscopy is standard UK practice.
-
What is intravesical BCG?
BCG is a live weakened bacterium instilled into the bladder through a catheter. It triggers a local immune response that reduces recurrence and progression in high-risk non-muscle-invasive bladder cancer.
-
What happens after a cystectomy?
Urine is diverted either through an ileal conduit to a stoma bag, or into a reconstructed neobladder. Specialist stoma and continence nurses guide recovery and daily life afterwards.
-
When should I worry about symptoms?
Any visible blood in the urine deserves urgent assessment. Massive bleeding with inability to pass urine, or fever after BCG or chemotherapy, needs same-day help.
Related content
Keep reading.
-
Cystoscopy
The telescope test used to look inside the bladder — diagnostic and therapeutic.
Learn more -
Flexible cystoscopy
The gold-standard first-line test for haematuria under local anaesthetic.
Learn more -
CT scan
Cross-sectional imaging used for upper-tract assessment and cancer staging.
Learn more -
All conditions
Browse the full Pulse Atlas library of clinically reviewed guides.
Learn more